SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-20-031340
Filing Date
2020-02-11
Accepted
2020-02-11 16:20:05
Documents
1
Group Members
CHRISTY SHAFFERCLAY B. THORPDOUGLAS REEDHATTERAS NC FUND, L.P.HATTERAS VENTURE ADVISORS IV SBIC, LLCHATTERAS VENTURE ADVISORS IV, LLCHATTERAS VENTURE ADVISORS V, LLCHATTERAS VENTURE PARTNERS IV, L.P.HATTERAS VENTURE PARTNERS V, L.P.JOHN C. CRUMPLERKENNETH

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d881899dsc13ga.htm SC 13G/A 201027
  Complete submission text file 0001193125-20-031340.txt   203173
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Subject) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90214 | Film No.: 20596868
SIC: 2834 Pharmaceutical Preparations

Mailing Address 280 S. MANGUM STREET SUITE 350 DURHAM NC 27701
Business Address 280 S. MANGUM STREET SUITE 350 DURHAM NC 27701 919-484-0730
Hatteras Venture Partners IV SBIC, LP (Filed by) CIK: 0001675232 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A